Determination of the starting dose in the first-in-human clinical trial of ERY974, a novel T cell-redirecting bispecific antibody targeting glypican-3, from MABEL and NOAEL approaches
EUROPEAN JOURNAL OF CANCER(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要